Document is current
Any future updates will be listed below
-
Authors
Ravano, Veronica https://orcid.org/0000-0002-1532-9664
Andelova, Michaela https://orcid.org/0000-0002-3812-7483
Piredda, Gian Franco https://orcid.org/0000-0002-8449-6634
Sommer, Stefan https://orcid.org/0000-0003-3484-1679
Caneschi, Samuele
Roccaro, Lucia
Krasensky, Jan https://orcid.org/0000-0002-5605-8821
Kudrna, Matej
Uher, Tomas https://orcid.org/0000-0003-3160-9022
Corredor-Jerez, Ricardo A. https://orcid.org/0000-0002-8172-9850
Disselhorst, Jonathan A. https://orcid.org/0000-0002-2924-1866
Maréchal, Bénédicte https://orcid.org/0000-0001-7866-2854
Hilbert, Tom https://orcid.org/0000-0001-8207-4908
Thiran, Jean-Philippe https://orcid.org/0000-0003-2938-9657
Richiardi, Jonas https://orcid.org/0000-0002-6975-5634
Horakova, Dana https://orcid.org/0000-0003-1915-0036
Vaneckova, Manuela https://orcid.org/0000-0001-6895-3738
Kober, Tobias https://orcid.org/0000-0001-7598-9456
-
Funding
Funding for this research was provided by:
Roche (NTC03706118)
Czech Ministry of Health (NU 22-04-001)
Charles University Hospital Prague (RVO VFN 64165)
Czech Ministry of Education (Project cooperation LF1)
EPFL Lausanne
- License Information
-
More Information
Article History
Received: 6 February 2024
Revised: 1 July 2024
Accepted: 5 July 2024
First Online: 13 July 2024
Declarations
:
: The authors of this manuscript declare relationships with the following companies: J-P. Thiran, M. Kudrna and J. Richiardi have no financial or proprietary interests in any material discussed in this article. V. Ravano, S. Sommer, R.A. Corredor-Jerez G.F. Piredda, J.A. Disselhorst, T. Hilbert, B. Maréchal and T. Kober are employed by Siemens Healthineers International AG, Switzerland. S. Caneschi and L. Roccaro were employed by Siemens Healthineers International AG, Switzerland. M. Vaneckova received compensation for speaker honoraria, travel and consultant fees from Biogen, Sanofi Genzyme, Novartis, Roche and Teva, as well as support for research activities from Biogen. J. Krasensky received financial support for research activities from Biogen Idec. M. Andelova received financial support for conference travel from Novartis, Genzyme, Merck Serono, Biogen Idec and Roche. T. Uher received financial support for conference travel from Biogen Idec, Novartis, Sanofi, Roche and Merck Serono and speaker honoraria from Biogen Idec, Novartis and Roche as well as support for research activities from Biogen Idec and Sanofi. K. Vodehnalova received compensation for traveling, conference fees and consulting fees from Merck, Teva, Sanofi Genzyme, Biogen Idec, Novartis, Roche. D. Horakova received compensation for travel, speaker honoraria, and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche and Teva, as well as support for research activities from Biogen Idec. She was also supported by the Czech Ministry of Education project Progress Q27/LF1.
: The study was conducted according to the Declaration of Helsinki and the local Ethics Committee provided approval for the examination of both MS patients and healthy individuals. All participants gave their written informed consent.
: Written informed consent was obtained from all patients in this study.
: Not applicable as no individual details are reported.
